Современные подходы к системному лечению BRCA-ассоциированного трижды негативного рака молочной железы

BRCA-ассоциированный трижды негативный рак молочной железы (ТНРМЖ) характеризуется высокой чувствительностью к ДНК-повреждающим цитотоксическим препаратам. Применение известных BRCA1/2-специфических противоопухолевых средств – производных платины и PARP-ингибиторов – длительное время обсуждалось в контексте лечения метастатического BRCA-ассоциированного ТНРМЖ. Стандартом лекарственной терапии первичного BRCA-ассоциированного РМЖ является неоадъювантная химиотерапия с использованием антрациклинов и таксанов. В настоящее время имеется не так много данных о добавлении препаратов платины к антрациклин-таксановой неоадъювантной химиотерапии при лечении первичного BRCA-ассоциированного ТНРМЖ. В представленном обзоре подробно описаны различные способы терапии данного рака, как первичного, так и метастатического. Показано, что разработка новых стратегий неоадъювантной химиотерапии для пациенток с первичным BRCA-ассоциированным ТНРМЖ является насущной клинической необходимостью для снижения рисков рецидивирования и прогрессирования.

1. Злокачественные новообразования в России в 2021 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старигородского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022. 252 с.

2. Desai N.V., Tung N.M. Medical management of newly diagnosed breast cancer in a BRCA1/2 mutation carrier. Breast J 2020; 26(8):1506–12. DOI: 10.1111/tbj.13972

3. Miki Y., Swensen J., Shattuck-Eidens D. et al. Strong candidate for the breast and ovarian cancer. Science 1994;266(5182):66–71. DOI: 10.1126/science.7545954

4. Wooster R., Neuhausen S.L., Mangion J. et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994;265(5181):2088–90. DOI: 10.1126/science.8091231

5. Antoniou A., Pharoah P.D., Narod S. et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72(5):1117–30. DOI: 10.1086/375033

6. Mavaddat N., Peock S., Frost D. et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 2013;105(11):812–22. DOI: 10.1093/jnci/djt095

7. Bianchini G., Balko J.M., Mayer I.A. et al. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol 2016;13:674–90. DOI: 10.1038/nrclinonc.2016.66

8. Geyer F., Pareja F., Weigelt B. et al.The spectrum of triple-negative breast disease: highand lowgrade lesions. Am J Pathol 2017;187(10):2139–51. DOI: 10.1016/j.ajpath.2017.03.016

9. Khosravi-Shahi P., Cabezón-Gutiérrez L., Custodio-Cabello S. Metastatic triple negative breast cancer: optimizing treatment options, new and emerging targeted therapies. Asia Pac J Clin Oncol 2018;14 (1):32–9. DOI: 10.1111/ajco.12748

10. Zeichner S.B., Terawaki H., Gogineni K. A review of systemic treatment in metastatic triple-negative breast cancer. Breast Cancer (Auckl) 2016;10:25–36. DOI: 10.4137/BCBCR.S32783

11. Tsai J., Bertoni D., Hernandez-Boussard T. et al. Lymph node ratio analysis after neoadjuvant chemotherapy is prognostic in hormone receptor-positive and triple-negative breast cancer. Ann Surg Oncol 2016;23(10):3310–6. DOI: 10.1245/s10434-016-5319-8

12. Copson E.R., Maishman T.C., Tapper W.J. et al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol 2018;19(2):169–80. DOI: 10.1016/S1470-2045(17)30891-4

13. Tassone P., Tagliaferri P., Perricelli A. et al. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer 2003;88(8):1285–91. DOI: 10.1038/ sj.bjc.6600859

14. Burness M.L., Obeid E.I., Olopade O.I. Triple negative breast cancer in BRCA1 mutation carriers with a complete radiologic response to neoadjuvant paclitaxel: a case report. Clin Breast Cancer 2015;15(2):e155-8. DOI: 10.1016/j.clbc.2014.08.006

15. Liedtke C., Mazouni C., Hess K.R. et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26(8):1275–81. DOI: 10.1200/ JCO.2007.14.4147

16. Paluch-Shimon S., Friedman E., Berger R. et al. Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triplenegative breast cancer among BRCA1 mutation carriers and noncarriers. Breast Cancer Res Treat 2016;157(1):157–65. DOI: 10.1007/s10549-016-3800-5

17. Weaver B.A. How taxol/paclitaxel kills cancer cells. Mol Biol Cell 2014;25(18):2677–81. DOI: 10.1091/mbc.E14-04-0916

18. Gluz O., Liedtke C., Gottschalk N. et al. Triple-negative breast cancer – current status and future directions. Ann Oncol 2009;20(12):1913–27. DOI: 10.1093/annonc/mdp492

19. Arun B., Bayraktar S., Liu D.D. et al. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. J Clin Oncol 2011;29(28):3739–46. DOI: 10.1200/JCO.2011.35.2682

20. Bignon L., Fricker J., Nogues C. et al. Efficacy of anthracycline/ taxanebased neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers. Breast J 2018;24(3): 269–77. DOI: 10.1111/tbj.12887

21. Desai N.V., Tung N.M. Medical management of newly diagnosed breast cancer in a BRCA1/2 mutation carrier. Breast J 2020;26(8): 1506–12. DOI: 10.1111/tbj.13972

22. Fong P.C., Boss D.S., Yap T.A. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361(2):123–34. DOI: 10.1056/NEJMoa0900212

23. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007;7(8):573–84. DOI: 10.1038/nrc2167

24. Byrski T., Huzarski T., Dent R. et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 2009;115(2):359–63. DOI: 10.1007/s10549-008-0128-9

25. Byrski T., Gronwald J., Huzarski T. et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 2010;28(3):375–9. DOI: 10.1200/JCO.2008.20.7019

26. Byrski T., Huzarski T., Dent R. et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 2009;115(2):359–63. DOI: 10.1007/s10549-008-0128-9

27. Silver D.P., Richardson A.L., Eklund A.C. et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 2010;28(7):1145–53. DOI: 10.1200/JCO.2009.22.4725

28. Loibl S., O’Shaughnessy J., Untch M. et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol 2018;19(4):497–509. DOI: 10.1016/S1470-2045(18)30111-6

29. Zhang J., Yao L., Liu Y. et al. Impact of the addition of carboplatin to anthracycline-taxane-based neoadjuvant chemotherapy on survival in BRCA1/2-mutated triple-negative breast cancer. Int J Cancer 2021;148(4):941–9. DOI: 10.1002/ijc.33234

30. Mrozek E., Kolesar J., Young D. et al. Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC). Ann Oncol 2008;19(8):1417–22. DOI: 10.1093/annonc/mdn154

31. Maisano R., Caristi N., Mare M. et al. Mitomycin C plus capecitabine (mixe) in anthracyclineand taxane-pretreated metastatic breast cancer. A multicenter phase II study. Anticancer Res 2007;27(4C):2871–5.

32. Holánek M., Bílek O., Nenutil R. et al. Effectiveness of neoadjuvant therapy with platinum-based agents for patients with BRCA1 and BRCA2 germline mutations – a retrospective analysis of breast cancer patients treated at MMCI Brno. Klin Onkol 2019;32(Suppl. 2): 31–5. DOI: 10.14735/amko2019S31

33. Banerjee S., Moore K.N., Colombo N. et al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial [published correction appears. Lancet Oncol 2021;22(12):1721–31. DOI: 10.1016/S1470-2045(21)00531-3

34. Arun B.K., Han H.S., Kaufman B. et al. Efficacy and safety of firstline veliparib and carboplatin-paclitaxel in patients with HER2-advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial. Eur J Cancer 2021;154:35–45. DOI: 10.1016/j.ejca.2021.05.037

35. Diéras V., Han H.S., Kaufman B. et al. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2020;21(10):1269–82. DOI: 10.1016/S1470-2045(20)30447-2

36. Han H.S., Diéras V., Robson M. et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Ann Oncol 2018;29(1):154–61. DOI: 10.1093/annonc/mdx505

37. Zhu Y., Wu J., Zhang C. et al. BRCA mutations and survival in breast cancer: an updated systematic review and meta-analysis. Oncotarget. 2016;7(43):70113–27. DOI: 10.18632/oncotarget.12158

38. Tutt A., Tovey H., Cheang M.C.U. et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med 2018;24(5):628–37. DOI: 10.1038/s41591-018-0009-7

39. Byrski T., Dent R., Blecharz P. et al. Results of a phase II openlabel, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. Breast Cancer Res 2012;14(4):R110. DOI: 10.1186/bcr3231

40. De Vos M., Schreiber V., Dantzer F. The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art. Biochem Pharmacol 2012;84(2):137–46. DOI: 10.1016/j.bcp.2012.03.018

41. Cortesi L., Rugo H.S., Jackisch C. An overview of PARP inhibitors for the treatment of breast cancer. Target Oncol 2021;16(3):255–82. DOI: 10.1007/s11523-021-00796-4

42. Robson M.E., Tung N., Conte P. et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol 2019;30(4):558–66. DOI: 10.1093/annonc/mdz012

43. Litton J.K., Rugo H.S., Ettl J. et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med 2018;379(8):753–63. DOI: 10.1056/NEJMoa1802905

44. Ayoub J.P., Wildiers H., Friedlander M. et al. Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline BRCA1/2 mutations and hormone receptor status from the phase-3 BROCADE3 trial. Ther Adv Med Oncol 2021;13:17588359211059601. DOI: 10.1177/17588359211059601

45. Rodler E., Sharma P., Barlow W.E. et al. Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, doubleblind, placebo-controlled, phase 2 trial. Lancet Oncol 2023;24(2):162–74. DOI: 10.1016/S1470-2045(22)00739-2

46. Stefansson O.A., Hilmarsdottir H., Olafsdottir K. et al. BRCA1 promoter methylation status in 1031 primary breast cancers predicts favorable outcomes following chemotherapy. JNCI Cancer Spectr 2019;4(2):pkz100. DOI: 10.1093/jncics/pkz100

47. Kawachi A., Yamashita S., Okochi-Takada E. et al. BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib/eribulin combination therapy. Breast Cancer Res Treat 2020;181(2):323–9. DOI: 10.1007/s10549-020-05647-w

48. Glodzik D., Bosch A., Hartman J. et al. Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers. Nat Commun 2020;11(1):3747. DOI: 10.1038/s41467-020-17537-2

49. Rice J.C., Ozcelik H., Maxeiner P. et al. Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens. Carcinogenesis 2000;21(9):1761–5. DOI: 10.1093/carcin/21.9.1761

50. Mo W., Liu Q., Lin C.C. et al. mTOR inhibitors suppress homologous recombination repair and synergize with PARP inhibitors via regulating SUV39H1 in BRCA-proficient triplenegative breast cancer. Clin Cancer Res 2016;22(7):1699–712. DOI: 10.1158/1078-0432.CCR-15-177